Archived Clinical Trials

  • CALGB 80403-ECOG 1206 - A Randomized Phase II Study of ECF-C, IC-C, or FOLFOX-C in Metastatic Esophageal and GE Junction Cancer - OverviewPDF document

  • CALGB 90202 - A Randomized, Double-Blind, Placebo-Controlled Phase III Study of Early versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone - OverviewPDF document

  • CALGB 90401 - A Randomized Double-Blinded Placebo Controlled Phase III Trial Comparing Docetaxel and Prednisone with and without Bevacizumab (IND #7921, NSC #704865) In Men with Hormone Refractory Prostate Cancer (Closed to Accrual, Effective 12/21/07) - OverviewPDF document

  • ECOG 1905 - A Randomized Phase II Trial of Azacitidine with or without the Histone Deacetylase Inhibitor MS-275 for the Treatment of Myelodysplatic Syndrome, Chronic Myelomonocytic Leukemia (Dysplastic Type), and Acute Myeloid Leukemia with Multilineage Dysplasia (Suspended to Accrual)

  • ECOG 1A05 - A Randomized Phase III Trial of Consolidation Therapy with Bortezomib (Velcade®)-Lenalidomide (Revlimid®) -Dexamethasone (VRD) Versus Bortezomib (Velcade®) Dexamethasone (VD) For Patients with Multiple Myeloma Who Have Completed a Dexamethasone Based Induction Regimen (Closed to Accrual, Effective May 7, 2010) - OverviewPDF document

  • ECOG 2204 - An Intergroup Randomized Phase II Study of Bevacizumab (NSC 704865) or Cetuximab (NSC 714692) in Combination with Gemcitabine and in Combination with Chemoradiation (Capecitabine and Radiation) in Patients with Completely Resected Pancreatic Carcinoma (Closed to Accrual, Effective 1/9/08) - OverviewPDF document

  • ECOG 2603 - A Double-blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and BAY 43-9006 versus Carboplatin, Paclitaxel and Placebo in Patients with Unresectable Locally Advanced or Stage IV Melanoma (closed to accrual April 22, 2008) - OverviewPDF document

  • ECOG 2805 ASSURE - A Randomized, Double Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma (Closed to Enrollment, Effective September 1, 2010) - OverviewPDF document

  • ECOG 5202 - A Randomized Phase III Study Comparing FOLFOX versus FOLFOX and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers (Closed to Enrollment, Effective February 11, 2011) - OverviewPDF document

  • ECOG 5204 - Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs. Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation (Closed to Accrual, Effective April 29, 2009) - OverviewPDF document

  • ECOG PACCT-1 - Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial (Closed to Registration, Effective October 6, 2010) - OverviewPDF document

  • GOG 0218 - A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC#704865, IND #7921) Followed By Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III (Suboptimal) and All Stage IV, Epithelial Ovarian, Primary Peritoneal Cancer or Fallopian Tube Cancer (Closed to Accrual) - OverviewPDF document

  • NCCTG N0147 - A Randomized Phase III Trial of Oxaliplatin Plus 5-Fluorouracil (5-FU)/ Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer (Permanently Closed to Accrual) - OverviewPDF document

  • NSABP B-42 - A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Cancer (Closed to Enrollment) - OverviewPDF document

  • NSABP R-04 - A Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with or without Oxaliplatin with Preoperative Radiation Therapy and Continuous Intravenous Infusion of 5-FU with or without Oxaliplatin in the Treatment of Patients with Operable Carcinoma of the Rectum (Closed to Enrollment, Effective August 16, 2010) - OverviewPDF document

  • PrECOG 0501 - A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination with Docetaxel and Carboplatin ± Placebo or Maintenance Therapy with Vandetanib in Patients with IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) - OverviewPDF document

  • RTOG 0212 - A Phase II/III Randomized Trial of Two Doses (Phase III- Standard vs. High) and Two High Dose Schedules (Phase II-Once vs. Twice Daily) For Delivering Prophylactic Cranial Irradiation for Patients with Limited Disease Small Cell Lung Cancer (Closed to Accrual, Effective February 12, 2008) - OverviewPDF document

  • RTOG 0229 - A Phase II Trial of Neoadjuvant Therapy with Concurrent Chemotherapy and High Dose Radiotherapy Followed by Surgical Resection and Consolidative Therapy for Locally Advanced NSCLC - OverviewPDF document

  • RTOG 0424 - A Phase II Study of Temozolomide-Based Chemoradiotherapy Regimen for High Risk Low-Grade Gliomas (Closed to Accrual) - OverviewPDF document

  • RTOG 0514 - Establishment of a Head and Neck Cancer Tissue/Specimen Repository - OverviewPDF document

  • RTOG 0522 - A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab (C225) [Followed by Surgery for Selected Patients] for Stage III and IV Head and Neck Carcinomas (Closed to Accrual) - OverviewPDF document

  • RTOG 0614 - A Randomized, Phase III, Double-Blind, Placebo-Controlled Trial of Memantine for Prevention of Cognitive Dysfunction in Patients Receiving Whole-Brain Radiotherapy (Closed to Accrual, Effective December 17, 2008) - OverviewPDF document

  • SWOG S0421 - A Phase III study of Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer (Closed) - OverviewPDF document

  • SWOG S0600 - Phase III Trial of Irinotecan Based Chemotherapy Plus Cetuximab With or Without Bevacizumab as Second Line Therapy for Patients with Metastatic Colorectal Cancer Who Have Progressed on Bevacizumab With Either FOLFOX, OPTIMOX, or XELOX (Closed to Enrollment, Effective November 10, 2010) - OverviewPDF document

© Copyright 2012, Meridian Health, Inc. | 732-840-2200

Ocean Medical Center | 425 Jack Martin Boulevard, Brick, NJ 08724